RxDoctor Payments Data

Karen Galichon, MD

Internal Medicine · New York, NYNPI 1447218193

Payments from drug & device makers

$3,596in general payments, 2019–2025

Across 200 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$861
  • Lilly USA, LLC$375
  • AstraZeneca$307
  • Amgen$220
  • Pfizer$208
  • AbbVie$196
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,579100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,596 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$119,488
Medicare patients
429
Services billed
1,151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide81$146,244
MounjaroTirzepatide83$132,773
FarxigaDapagliflozin Propanediol49$55,704
EliquisApixaban54$53,391
JardianceEmpagliflozin38$50,531
OzempicSemaglutide35$41,943
XareltoRivaroxaban20$17,498
Atorvastatin Calcium537$5,340
Rosuvastatin Calcium473$5,015
Pregabalin37$4,524
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$4,243
Losartan Potassium477$4,004
Levothyroxine Sodium305$3,523
SynthroidLevothyroxine Sodium79$3,320
Amlodipine Besylate549$3,051

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$375$279,017164 claims
AstraZenecaFarxiga$307$55,70449 claims
PfizerEliquis$208$53,39154 claims
Boehringer IngelheimJardiance$118$50,53138 claims
Novo NordiskOzempic$861$41,94335 claims
Johnson & JohnsonXarelto$168$17,49820 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$3,523305 claims
AbbVieSynthroid$196$3,32079 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →